Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for allergic bronchopulmonary aspergillosis
NL-OMON56225Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic bronchopulmonary aspergillosis (ABPA) and asthma comparing Dupilumab with Placebo (2 arms). Primary endpoint: Change from baseline in pre-bronchodilator FEV1. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)asthma
Beyond the preview
Go deeper on NL-OMON56225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56225.